NCT07516509招募中不适用
Determining Cell- and Spatially-distinct Skeletal Muscle Transcriptional Aberrations With Insulin Resistance
AdventHealth Translational Research Institute2 个研究点 分布在 1 个国家目标入组 36 人开始时间: 2026年6月11日最近更新:
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 36
- 试验地点
- 2
- 主要终点
- Skeletal muscle insulin sensitivity
研究概览
简要总结
The purpose of this study is to find new signs or signals in muscle cells that can help us understand when the body isn't responding well to insulin (a condition called insulin resistance).
详细描述
The primary goal of this research is to look at gene expression changes to insulin stimulation in different cells and areas of skeletal muscle and how they are affected by obesity and insulin resistance. The investigators are studying sedentary men and women between the ages of 30 and 65 years with; either a body mass index (BMI) between 18-25 kg/m2 or 30-40 kg/m2
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Cross Sectional
入排标准
- 年龄范围
- 30 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •All Groups
- •30 to 65 years of age
- •Stable weight (No Gain/Loss of >10 lbs in 6 months)
- •Sedentary (≤ 1 continuous exercise/week)
- •Resting Blood Pressure ≤ 150mmHg systolic and ≤ 95 mmHg diastolic
- •Group A - Lean individuals with insulin sensitivity (IS-Lean)
- •BMI 18-25 kg/m2
- •Hemoglobin A1c ≤ 5.6% at screening
- •Blood glucose level ≤ 140 mg/dL 2hr after a 75g oral glucose tolerance test
- •Group B - Individuals with obesity and insulin sensitivity (IS-Obesity)
- •BMI 30-40 kg/m2
- •Hemoglobin A1c ≤ 5.6% at screening
- •Blood glucose level ≤ 140 mg/dL 2hr after a 75g oral glucose tolerance test
- •Group C - Individuals with obesity and insulin resistance (IR-Obesity)
- •BMI 30-40 kg/m2
- •Hemoglobin A1c ≤ 6.4 % at screening
- •Blood glucose level 140-199 mg/dL 2hr after a 75g oral glucose tolerance test
排除标准
- •Clinically significant CVD including h/o MI, within the past year
- •Peripheral Vascular Disease
- •Diagnosed with Type I or Type II diabetes
- •Hepatic, renal, muscular/neuromuscular, or active hematologic/oncologic disease
- •Previous history of pulmonary emboli
- •Peripheral Neuropathy
- •Anemia (Hematocrit <34%, Hemoglobin < 14 gm/dL for men and <12.3 gm/dL for women) at screening
- •Currently pregnant (pregnancy test performed on day of DEXA scan in women of child-bearing potential); post-partum during the last 12 months; lactating during the last 12 months; planning to become pregnant during the participation period
- •Polycystic Ovarian Syndrome (PCOS) (self-report)
- •Hospitalization for COVID-19 infection in the past 12 months; individuals who tested positive for COVID-19 but were not hospitalized must be symptom-free at least 14 days
- •Partial and/or full hysterectomy (self-report)
- •Not willing to archive biospecimens for future use
- •Any contraindications to exercise testing according to ACSM guidelines
- •Inability and/ or unwillingness to comply with the protocol as written
- •Active alcohol or substance abuse (Past 5 Years)
- •Positive toxicology result from screening visit or chronic use of Amphetamine, Barbiturate, Benzodiazepine, Cocaine, Methadone, Opiate, THC, Cannabis, Tricyclics, or Oxycodone.
- •Dyslipidemia (fasting triglycerides >500 mg/dL; low-density lipoprotein cholesterol (LDL-C) >190 mg/dL; total cholesterol >300 mg/dL);
- •ALT >80, AST>80, Alk Phos >240 if a participant presents with liver functions out of these ranges at screening the MI or PI can give discretion to participate
- •Proteinuria (defined as > 1+) at screening
- •Kidney disease (creatinine >1.6 mg/dl or estimated glomerular filtration rate <60 mL/min/1.73m2);
- •Self-reported chronic, active, or latent infection requiring chronic antibiotic or anti-viral treatment; Human Immunodeficiency Virus (HIV); active hepatitis B or C undergoing antiviral therapy.
- •Receiving active treatment (including monoclonal antibodies) for autoimmune disorders within the last 6 months;
- •Hypothyroidism (sTSH>8) at screening or on thyroid replacement therapy
- •Abnormal bleeding or coagulopathy (self-report) or history of a bleeding disorder or clotting abnormality
- •History of cancer (other than non-melanoma skin cancer) within the last 5 years (not in remission); anti-hormonal therapy (e.g., for breast or prostate cancer) within the last 6 months;
- •Previous bariatric or other surgery for obesity
- •Females currently on hormone replacement therapy (HRT) less than 6 months
- •Females with an irregular menstrual cycle
- •Previous difficulty with lidocaine or other local anesthetic
- •ACS symptoms:
- •Positive ECG (> 2mm ST segment depression) without PCP cardiologist permission to participate
- •Signs or symptoms of cardiovascular decomposition (eg. hypotensive response to exercise)
- •Onset of angina or angina like symptoms, shortness of breath, change in heart rhythm, signs of poor perfusion (light-headedness), tightness.
- •The following medication use is exclusionary;
- •Dose change for any chronic-use drug in the last 3 months;
- •Any medications that can alter glucose homeostasis (eg. steroids, glucocorticoids, nicotinic acid). Acute therapy (5-7 days) is not exclusionary however; participant must be agreeable to a washout period of 5-7 days prior to day of biopsy.
- •Blood thinners such as Coumadin, Lovenox etc. Aspirin is not exclusionary however; participant must be agreeable to a washout period of > 10 days prior to day of biopsy
- •All Weight loss medications including but not limited toGLP-1 agonists- Wegovy, liraglutide, semaglutide, Trulicity (dulaglutide), Phentermine and Contrave
- •Cardiovascular: beta blockers and centrally acting anti-hypertensive drugs, anticoagulants, antiarrhythmics, and antiplatelet drugs (other than aspirin ≤100 mg/day);
- •Psychiatric: chronic use of medium- or long-acting sedatives and hypnotics, including all benzodiazepines (short-acting non-benzodiazepine sedative-hypnotics are allowed), mood stabilizers, antiepileptic drugs, stimulants, Attention-Deficit/Hyperactivity Disorder (ADHD) drugs, anti-psychotic drugs, anti-depressant medication (e.g. Bupropion, selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine re-uptake inhibitors (SNRIs)).
- •Pulmonary/Inflammation: chronic oral steroids (occasional use of inhaled steroids are allowed), burst/taper oral steroids more than once in the last 12 months, B2-agonists (allowed if on stable dose at least 3 months).
- •Genitourinary: 5-alpha reductase inhibitors, daily use of phosphodiesterase type 5 inhibitor.
- •Hormonal: androgenic anabolic steroids, anti-estrogens, anti-androgens, estrogens and/or progestins used for reasons other than birth control, growth hormone, insulin like growth factor-I, growth hormone releasing hormone,
- •any drugs used to treat diabetes mellitus or lower blood glucose including metformin, thiazolidinediones, SGLT-2 inhibits or insulin
- •any drugs used specifically to induce muscle growth/hypertrophy or augment exercise-induced muscle hypertrophy
- •Pain/Inflammation: narcotics and narcotic receptor agonists, regular use of non-steroidal anti-inflammatory drugs (NSAIDs) or acetaminophen, muscle relaxants ≥2 days per week
- •Other: chronic systemic antimicrobials (antibiotic, antiviral, antifungal, antiparasite, etc.) for any reason, high-potency topical steroids if ≥10% surface area using rule of 9s, continuous/chronic use of antibiotics or other anti-infectives for treatment or prevention, monoclonal antibodies, anti-rejection medications/immune suppressants. Participants can be re-screened after a 3 month washout period if antimicrobial use is only used acutely < 2 weeks.
- •Presence of any condition that, in the opinion of the Investigator, compromises participant safety or data integrity or the participant's ability to complete the study.
研究组 & 干预措施
Group C - Individuals with obesity and insulin resistance (IR-Obesity)
干预措施: Non-Oxidative Glucose Disposal (Other)
Group C - Individuals with obesity and insulin resistance (IR-Obesity)
干预措施: Muscle tissue Biopsy (Other)
Group A - Lean individuals with insulin sensitivity (IS-Lean)
干预措施: VO2 Max (Other)
Group A - Lean individuals with insulin sensitivity (IS-Lean)
干预措施: Non-Oxidative Glucose Disposal (Other)
Group A - Lean individuals with insulin sensitivity (IS-Lean)
干预措施: Muscle tissue Biopsy (Other)
Group C - Individuals with obesity and insulin resistance (IR-Obesity)
干预措施: DEXA (Other)
Group B - Individuals with obesity and insulin sensitivity (IS-Obesity)
干预措施: VO2 Max (Other)
Group B - Individuals with obesity and insulin sensitivity (IS-Obesity)
干预措施: DEXA (Other)
Group B - Individuals with obesity and insulin sensitivity (IS-Obesity)
干预措施: Peripheral Microvascular Reactivity (Other)
Group B - Individuals with obesity and insulin sensitivity (IS-Obesity)
干预措施: Non-Oxidative Glucose Disposal (Other)
Group B - Individuals with obesity and insulin sensitivity (IS-Obesity)
干预措施: Muscle tissue Biopsy (Other)
Group C - Individuals with obesity and insulin resistance (IR-Obesity)
干预措施: VO2 Max (Other)
Group C - Individuals with obesity and insulin resistance (IR-Obesity)
干预措施: Skeletal Muscle Insulin Sensitivity (Other)
Group A - Lean individuals with insulin sensitivity (IS-Lean)
干预措施: DEXA (Other)
Group B - Individuals with obesity and insulin sensitivity (IS-Obesity)
干预措施: Skeletal Muscle Insulin Sensitivity (Other)
Group C - Individuals with obesity and insulin resistance (IR-Obesity)
干预措施: Peripheral Microvascular Reactivity (Other)
Group A - Lean individuals with insulin sensitivity (IS-Lean)
干预措施: Peripheral Microvascular Reactivity (Other)
Group A - Lean individuals with insulin sensitivity (IS-Lean)
干预措施: Skeletal Muscle Insulin Sensitivity (Other)
结局指标
主要结局
Skeletal muscle insulin sensitivity
时间窗: 6.5 hours
Skeletal muscle insulin sensitivity will be quantified with the HE clamp and compared between groups.
Skeletal muscle cell composition
时间窗: 30 minutes
Cell composition will be assessed with single cell RNA-seq and spatial transcriptomics and compared between the groups
Cell and Region Specific Transcriptomic profiles
时间窗: 9 months
Cell and region specific, basal and insulin-induced transcriptomic profiles will be assessed using scRNA-seq and spatial transcriptomics and compared between the groups
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
招募中
不适用
Muscle Health Measurements Using Electrical Impedance MyographyMyopathyMuscular DystrophiesMyofibrillar MyopathyCongenital MyopathyDistal MyopathyMyopathiesMyositisNCT07502989Beth Israel Deaconess Medical Center150
已完成
不适用
Regulation of Satellite Cells and Myogenesis in Response to Eccentric Resistance Exercise in HypoxiaNCT07341165Université Catholique de Louvain38
招募中
不适用
A Muscle-brain Interplay Study in Neurological DisordersNCT07477821Istituti Clinici Scientifici Maugeri SpA150
招募中
不适用
Exercise Training Effects on Muscle Function in Adults With Mitochondrial MyopathyNCT07450690University of Copenhagen22
Unknown
不适用
不同关节角度下等长收缩过程中主动肌与拮抗肌的力学和肌电信号的分析ChiCTR-ROC-17012429南方医科大学南方医院21